|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's Range||36.08 - 36.43|
|52 Week Range||30.20 - 36.62|
|PE Ratio (TTM)||157.65|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A Relative Strength Rating upgrade for Qiagen shows improving technical performance. Will it continue?
The Venlo, Netherlands-based company said it had net income of 14 cents per share. Earnings, adjusted for non-recurring costs, came to 26 cents per share. The results beat Wall Street expectations. The ...
QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.
On a per-share basis, the Venlo, Netherlands-based company said it had a loss of 18 cents. Earnings, adjusted for non-recurring costs, were 43 cents per share. The results topped Wall Street expectations. ...
QIAGEN NV (NYSE:QGEN), a life sciences company based in Netherlands, saw a decent share price growth in the teens level on the NYSE over the last few months. With manyRead More...
Small market caps, attractive growth prospects and idiosyncratic product cycles among diagnostics companies can lead to valuation volatility while also creating attractive M&A opportunities. The Analyst ...
QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.